NCT07298954 is a NA clinical trial of sequential combined AVS in Primary Aldosteronism, sponsored by Shumin Yang.

Who is sponsoring NCT07298954?

NCT07298954 is sponsored by Shumin Yang.

What drugs are being tested in NCT07298954?

Interventions in NCT07298954: sequential combined AVS.

What condition does NCT07298954 study?

NCT07298954 studies Primary Aldosteronism.

Is NCT07298954 still recruiting?

NCT07298954 is currently recruiting now. Last updated 24 December 2025.

Last reviewed 2025-12-24 · How we verify

NCT07298954

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism(SCOPE)

Recruiting now NA Last updated 24 December 2025

What this trial tests

NA trial testing sequential combined AVS in Primary Aldosteronism in 456 participants. Currently enrolling.

Timeline

25 December 2025

Primary endpoint
31 December 2027

31 December 2028

Quick facts

Lead sponsor	Shumin Yang
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	456
Start date	25 December 2025
Primary completion	31 December 2027
Estimated completion	31 December 2028
Sites	1 location across China

Drugs / interventions tested

sequential combined AVS

Conditions studied

Primary Aldosteronism — all drugs for Primary Aldosteronism →

Sponsor

Shumin Yang

Who can join

Adults 18 to 70, any sex, with Primary Aldosteronism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, multicenter, randomized clinical trial aimed to compare the impact of three AVS diagnostic strategies on the clinical outcomes of patients with primary aldosteronism. The strategies include sequential combined AVS (non-ACTH-stimulated followed by ACTH-stimulated AVS), non- ACTH-stimulated AVS alone, and ACTH-stimulated AVS alone. The findings of this study will provide critical evidence for the clinical practice standards of AVS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Primary Aldosteronism

Currently open trials in the same condition.

NCT07111351 — Multi-omics Studies of Primary Aldosteronism · recruiting
NCT07027254 — PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism · NA · recruiting
NCT06941116 — Steroids-Based Screening for Primary Aldosteronism · recruiting
NCT06955286 — Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Witho · recruiting
NCT06740838 — Overnight Dexamethasone in Primary Aldosteronism Screening · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07298954 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shumin Yang
Last refreshed: 24 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07298954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing